Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

PTX3 (human) detection set [for ELISA application]

 
ALX-850-299-KI01 1 Set 909.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:Pentraxin 3, TSG14, TNF stimulated Gene-14
 
Sensitivity:Detection limit: 75pg/ml.
 
Applications:ELISA
 
Application Notes:For the quantitative determination of PTX3 in human and bovine (weak) cell culture media, EDTA-plasma or serum (weak) samples.
 
Species reactivity:Human
 
Kit/Set Contains:Contains enough material to prepare 10 plates:
- 1 vial (10µg) PTX3 (human) (rec.) (Prod. No. ALX-201-124)
- 1 vial (50µg) PTX3, pAb (Biotin) [Detection Antibody] (Prod. No. ALX-210-365B)
- 1 vial (100µg) PTX3, mAb (MNB4) [Capture Antibody] (Prod. No. ALX-804-464)
 
Use/Stability:Once thawed store biotinylated antibody at 4°C and do not re-freeze.
 
Handling:Avoid freeze/thaw cycles.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Scientific Background:Pentraxin 3 (PTX3), a member of the pentraxin family, is referred to as a long pentraxin and contains a unique PTX3 domain not found in C-reactive protein (CRP) or (Serum Amyloid P component) SAP. In contrast to CRP, PTX3 is produced from the major cell types involved in atherosclerotic lesions, namely vascular endothelial cells, vascular smooth muscle cells, macrophages, and nutrophils in response to inflammatory stimuli. Moreover, CRP is produced by the liver and represents a systemic response to local inflammation, whereas PTX3 is rapidly produced directly from damaged tissues and directly reflects the inflammatory state of the vasculature. PTX3 levels have been reported to be significantly elevated in acute myocardial infarction, and accordingly, statin treatment significantly decreases PTX3 levels. Due to the fact that PTX3 is able to reflect acute coronary syndrome (ACS) condition better than CRP, it is highly possible that PTX3 is a superior biomarker to predict future cardiovascular events.
 
Protocol:Sandwich ELISA for PTX3
  1. 96 well-ELISA plates (Nunc MaxiSorp 446612) were coated with 100µl of MAb to PTX3 (human) (MNB4) (Prod. No. ALX-804-464), 1μg/ml in 100µl coating buffer (15mM carbonate buffer pH 9.6) and incubated overnight at 4°C.
  2. After incubation, the plates were washed three times with 300µl/well of washing buffer (PBS + 0.05% Tween 20), and then 300µl of 5% dry milk in washing buffer were added to block non-specific binding.
  3. The plates were incubated for 2 hours at room temperature and then washed three times with washing buffer.
  4. 50µl (in duplicate) recombinant human PTX3 standard (Prod. No. ALX-201-124) (75pg/ml to 2.4ng/ml ), cell supernatants or biological fluids diluted in PBS without Ca and Mg + 2% BSA were added and then incubated for 2 hours at 37°C.
  5. The plates were washed five times with washing buffer, and then 100µl of PAb to PTX3 (human) (Biotin) (Prod. No. ALX-210-365B) 50ng/ml in washing buffer were added in each well.
  6. The plates were incubated for 1 hour at 37°C and then washed five times with 300µl of washing buffer.- 100 µl/well streptavidin-horseradish peroxidase diluted 1:4’000 were added and the plates incubated for 1 hour at room temperature.
  7.  After incubation the plates were washed 5 times with washing buffer and 100µl of TMB substrate solution was added to each well. After incubation for 10 min. at room-temperature, 50μl of stop-solution (1M H2SO4) was added. Subsequently, absorbance was read within 30min at 450nm.

Note: Do not use heparin plasma or serum samples with this assay. EDTA samples are recommended. The detection value in serum is generally less than in plasma samples.

 
UniProt ID:P26022
 

Product Literature References

Diverging trajectory patterns of systemic versus vascular inflammation over age in healthy Caucasians and African-Americans: B. Enkhmaa, et al.; Atherosclerosis 239, 509 (2015), Application(s): ELISA using human blood, Abstract;
Age as a Modulator of Inflammatory Cardiovascular Risk Factors: E. Anuurad, et al.; Arterioscler. Thromb. Vasc. Biol. 31, 2151 (2011), Abstract;
Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians : B. Enkhmaa, et al.; Transl. Res. 158, 92 (2011), Abstract;
Early and Transient Release of Leukocyte Pentraxin 3 during Acute Myocardial Infarction: N. Maugeri, et al.; J. Immunol. 187, 970 (2011), Abstract;
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3: T. Barbui, et al.; Haematologica 96, 315 (2011), Abstract; Full Text
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells: G. Germano, et al.; Cancer Res. 70, 2235 (2010), Abstract;
Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy: S. Galbiati, et al.; Clin. Chem. Lab. Med. 48, 791 (2010), Abstract;
Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis: R. Dubin, et al.; Nephrol. Dial. Transplant. 26, 1903 (2010), Abstract;
Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile: M. Zanetti, et al.; Clin. Exp. Med. 9, 243 (2009), Abstract;
Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line: S.L. Rebelo, et al.; Arthritis Rheum. 60, 269 (2009), Abstract;
Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3: A. Bosutti, et al.; J. Clin. Endocrinol. Metab. 93, 3226 (2008), Abstract;
Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris: K. Inoue, et al.; Arterioscler. Thromb. Vasc. Biol. 27, 161 (2007), Abstract; Full Text
Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease: M. Boehme, et al.; Nephrol. Dial. Transplant. 22, 2224 (2007), Abstract;
The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells: P. Baruah, et al.; J. Leukoc. Biol. 80, 87 (2006), Abstract; Full Text
TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK: B. Han, et al.; J. Immunol. 175, 8303 (2005), Abstract; Full Text
DNA microarray analysis of gene expression in alveolar epithelial cells in response to TNFalpha, LPS, and cyclic stretch: C.C. dos Santos, et al.; Physiol. Genomics 19, 331 (2004), Abstract; Full Text
PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans: G. Peri, et al.; Circulation 102, 636 (2000), Abstract; Full Text

General Literature References

Pathogen Recognition by the Long Pentraxin PTX3: F. Moalli, et al.; J. Biomed. Biotechnol. 830421 (2011), Abstract; Full Text

Related Products

PTX3 (human), (recombinant) 

Produced in CHO cells. Human full-length PTX3., ELISA, WB | Print as PDF
 
ALX-201-124-C010 10 µg 379.00 USD
Do you need bulk/larger quantities?
 

PTX3 polyclonal antibody (biotin conjugate) 

ELISA, ICC, IHC | Print as PDF
 
ALX-210-365B-C050 50 µg Biotin 552.00 USD
Do you need bulk/larger quantities?
 

PTX3 monoclonal antibody (MNB4) 

ELISA, Flow Cytometry, IHC (FS), IP, WB | Print as PDF
 
ALX-804-464-C100 100 µg 430.00 USD
Do you need bulk/larger quantities?
 

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
PTX3
By biological activity:
PTX3 ELISA development kit
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Catalogs
Immunoassay Kits
Immunoassay Kits
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,